Cargando…
A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design
The design of well-powered in vivo preclinical studies is a key element in building knowledge of disease physiology for the purpose of identifying and effectively testing potential anti-obesity drug targets. However, as a result of the complexity of the obese phenotype, there is limited understandin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568066/ https://www.ncbi.nlm.nih.gov/pubmed/28392555 http://dx.doi.org/10.1038/ijo.2017.93 |
_version_ | 1783258796937707520 |
---|---|
author | Selimkhanov, Jangir Thompson, W. Clayton Guo, Juen Hall, Kevin D. Musante, Cynthia J. |
author_facet | Selimkhanov, Jangir Thompson, W. Clayton Guo, Juen Hall, Kevin D. Musante, Cynthia J. |
author_sort | Selimkhanov, Jangir |
collection | PubMed |
description | The design of well-powered in vivo preclinical studies is a key element in building knowledge of disease physiology for the purpose of identifying and effectively testing potential anti-obesity drug targets. However, as a result of the complexity of the obese phenotype, there is limited understanding of the variability within and between study animals of macroscopic endpoints such as food intake and body composition. This, combined with limitations inherent in the measurement of certain endpoints, presents challenges to study design that can have significant consequences for an anti-obesity program. Here, we analyze a large, longitudinal study of mouse food intake and body composition during diet perturbation to quantify the variability and interaction of key metabolic endpoints. To demonstrate how conclusions can change as a function of study size, we show that a simulated pre-clinical study properly powered for one endpoint may lead to false conclusions based on secondary endpoints. We then propose guidelines for endpoint selection and study size estimation under different conditions to facilitate proper power calculation for a more successful in vivo study design. |
format | Online Article Text |
id | pubmed-5568066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
record_format | MEDLINE/PubMed |
spelling | pubmed-55680662017-10-10 A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design Selimkhanov, Jangir Thompson, W. Clayton Guo, Juen Hall, Kevin D. Musante, Cynthia J. Int J Obes (Lond) Article The design of well-powered in vivo preclinical studies is a key element in building knowledge of disease physiology for the purpose of identifying and effectively testing potential anti-obesity drug targets. However, as a result of the complexity of the obese phenotype, there is limited understanding of the variability within and between study animals of macroscopic endpoints such as food intake and body composition. This, combined with limitations inherent in the measurement of certain endpoints, presents challenges to study design that can have significant consequences for an anti-obesity program. Here, we analyze a large, longitudinal study of mouse food intake and body composition during diet perturbation to quantify the variability and interaction of key metabolic endpoints. To demonstrate how conclusions can change as a function of study size, we show that a simulated pre-clinical study properly powered for one endpoint may lead to false conclusions based on secondary endpoints. We then propose guidelines for endpoint selection and study size estimation under different conditions to facilitate proper power calculation for a more successful in vivo study design. 2017-04-10 2017-08 /pmc/articles/PMC5568066/ /pubmed/28392555 http://dx.doi.org/10.1038/ijo.2017.93 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Selimkhanov, Jangir Thompson, W. Clayton Guo, Juen Hall, Kevin D. Musante, Cynthia J. A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title | A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title_full | A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title_fullStr | A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title_full_unstemmed | A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title_short | A quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
title_sort | quantitative analysis of statistical power identifies obesity endpoints for improved in vivo preclinical study design |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568066/ https://www.ncbi.nlm.nih.gov/pubmed/28392555 http://dx.doi.org/10.1038/ijo.2017.93 |
work_keys_str_mv | AT selimkhanovjangir aquantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT thompsonwclayton aquantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT guojuen aquantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT hallkevind aquantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT musantecynthiaj aquantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT selimkhanovjangir quantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT thompsonwclayton quantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT guojuen quantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT hallkevind quantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign AT musantecynthiaj quantitativeanalysisofstatisticalpoweridentifiesobesityendpointsforimprovedinvivopreclinicalstudydesign |